[A22-97] Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53

Last updated 20.10.2022

Project no.:
A22-97

Commission:
Commission awarded on 06.09.2022 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after complete resection

Result of dossier assessment:

Unchanged after addendum:

  • Patients who are eligible for cisplatin-containing therapy for adjuvant treatment: added benefit not proven
  • Patients who are not eligible for cisplatin-containing therapy for adjuvant treatment: hint of minor added benefit
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2022-10-20 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form